Influence of targeted therapy on curative effect and survival of multiple myeloma patients / 白血病·淋巴瘤

ABSTRACT

Objective To investigate the influence of molecular targeted therapy (thalidomide,lenalidomide or bortezomib) on survival and curative effect of patients with multiple myeloma (MM).Methods The treatment of 217 patients diagnosised as MM from 1998 to 2013 were reviewed.The survival of patients who were diagnosed during different periods were compared,and the impact of improved treatment on the survival and curative effect of patients were analyzed.Results Patients who were recently diagnosed as MM after 1998 had better survival.75 patients with targeted therapy (thalidomide or bortezomib) for their early treatment had better survival compared to the patients with conventional treatments of MP/VAD.49 patients with targeted therapy after relapse or progression had a better curative effect than those with conventional treatments.16 patients had auto-ASCT or allo-SCT,and 4 of them had both auto-ASCT and allo-SCT,who had better survival than patients without transplantation.Conclusion Patients treated with molecular targeted therapy (thalidomide,lenalidomide,bortezomib) had a better curative effect and longer survival.